Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by eric40on Jul 06, 2017 7:52pm
236 Views
Post# 26442523

RE:RE:Response from fred to my questions.

RE:RE:Response from fred to my questions.Obviously, Fred won't over promise on revenu. If he did, people would say he is pumping.

I'd rather his answer and make my own calculation based on production capacity for IVIG as IVIG will be sold in bulk without the need of marketing effort.

About Plasminogen, Prometic has a good estimation of the PgCD market, However, there is a potential larger market as Plasminogen healing effect are known in the medical world, especialy in the top tier hospital. And guess what, this is where PgCD is normally treated and this is where the marketing team is concentrating it's efforts.

After one year on the market for Pg, we could be surprised by the quantity of PG sold.

And for  the BLA, it is not a matter of if, but when it will be approved. And I am confident that the regulatory timeframe for the approval will be respected for reasons I have already discuss in previous post.

This is summertime, unless there is a US market correction , I am confident that the next 3 months will bring the share price back to new high.



Bullboard Posts